Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease

Ren H., Elliott N., Lye B., Sharif Shohan MU., Cross JW., Field L., Ponnusamy K., Rice S., Jackson T., Leontari I., Ouazzani NE., Thomas R., Inglott S., Bartram J., Smith O., Bond J., Roberts IAG., Halsey C., Bashford-Rogers R., Milne TA., Roy A., Karadimitris A.

DOI

10.1101/2025.01.22.633541

Type

Preprint

Publication Date

24/01/2025

Permalink Original publication